Want to see KYNB full AI Analyst Report?
KYNB Stock Chart & Stats
$7.32
>-$0.01(-1.28%)
At close: 4:00 PM EST
$7.32
>-$0.01(-1.28%)
Day’s Range― - ―
52-Week Range$5.37 - $12.60
Previous CloseN/A
VolumeN/A
Average Volume (3M)30.76K
Market Cap
$30.89M
Enterprise Value$10.22M
Total Cash (Recent Filing)$87.24M
Total Debt (Recent Filing)$19.25M
Price to Earnings (P/E)0.2
Beta0.78
Next Earnings
Aug 10, 2026EPS Estimate
-3.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)41.56
Shares Outstanding4,048,112
10 Day Avg. Volume33,010
30 Day Avg. Volume30,760
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-1.18
Price to Sales (P/S)5.51
P/FCF Ratio-7.38
Enterprise Value/Market Cap0.33
Enterprise Value/Revenue1.37
Enterprise Value/Gross Profit3.05
Enterprise Value/Ebitda-0.18
Forecast
1Y Price Target
$36.50Price Target Upside398.63% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-13.89
Revenue Forecast (FY)$5.15M
Bulls Say, Bears Say
Bulls Say
Cash RunwayA >$100M liquidity stockpile with management guidance to fund U.S. pipeline activities into 2028 materially reduces near-term financing pressure and gives time to execute Phase II/III milestones. This durable runway supports trial completion and strategic optionality over the next 2–6 months.
No Financial LeverageZero reported debt lowers refinancing and interest risk and enhances financial flexibility to fund development programs or pursue partnerships. Over a multi-month horizon this reduces insolvency risk and provides capacity to prioritize R&D spending without immediate covenant constraints.
Defined Clinical Milestones & Biomarker PathClear, time-bound development milestones and a potential companion diagnostic (CD46 PET) create a structured value-creation path. Constructive FDA feedback on roxadustat and a defined Phase II interim target make clinical execution the central driver, giving investors a measurable timetable for durable program de‑risking.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow imply recurring cash consumption from operations despite some improvement. This structural burn keeps the company dependent on non‑operating funding, deal proceeds or equity raises and increases execution risk if clinical timelines slip or costs rise.
Weak Operating Profitability & Negative EquityMaterial negative operating margins and negative shareholders' equity weaken the company's financial resilience. Over several months this reduces the cushion to absorb setbacks, complicates partnering or borrowing negotiations, and raises questions about earnings quality given net income is not supported by operating cash flow.
Nasdaq Compliance RiskAn active Nasdaq non‑compliance notice is a structural listing overhang until remedied and can force strategic actions (plan submission, listing transfer, or capital raising). This uncertainty materially affects governance and strategic flexibility and could constrain partnership or financing options over the coming months.
Kyntra Bio News
KYNB FAQ
What was Kyntra Bio’s price range in the past 12 months?
Kyntra Bio lowest stock price was $5.37 and its highest was $12.60 in the past 12 months.
What is Kyntra Bio’s market cap?
Kyntra Bio’s market cap is $30.89M.
When is Kyntra Bio’s upcoming earnings report date?
Kyntra Bio’s upcoming earnings report date is Aug 10, 2026 which is in 37 days.
How were Kyntra Bio’s earnings last quarter?
Kyntra Bio released its earnings results on May 11, 2026. The company reported -$3.76 earnings per share for the quarter, missing the consensus estimate of -$3.355 by -$0.405.
Is Kyntra Bio overvalued?
According to Wall Street analysts Kyntra Bio’s price is currently Undervalued.
Does Kyntra Bio pay dividends?
Kyntra Bio does not currently pay dividends.
What is Kyntra Bio’s EPS estimate?
Kyntra Bio’s EPS estimate is -3.27.
How many shares outstanding does Kyntra Bio have?
Kyntra Bio has 4,048,112 shares outstanding.
What happened to Kyntra Bio’s price movement after its last earnings report?
Kyntra Bio reported an EPS of -$3.76 in its last earnings report, missing expectations of -$3.355. Following the earnings report the stock price went up 6.25%.
Which hedge fund is a major shareholder of Kyntra Bio?
Currently, no hedge funds are holding shares in KYNB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kyntra Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$36.50 (398.63% Upside)
$36.50 (398.63% Upside)
Hedge Fund Trend
Decreased
By 58.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $19.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 3.9%
Last 30 Days ▼ 3.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
5.11%
12-Months-Change
Fundamentals
Return on Equity
-234.28%
Trailing 12-Months
Asset Growth
-33.64%
Trailing 12-Months
Company Description
Kyntra Bio
Kyntra Bio, Inc. functions as a biopharmaceutical enterprise, encompassing the entire process from the initial discovery and rigorous development of innovative treatments to their ultimate market introduction. The company's scientific focus delves into the complex biology of hypoxia-inducible factors (HIF) and connective tissue growth factors (CTGF). Through this research, Kyntra Bio strives to create groundbreaking therapies aimed at tackling conditions like anemia, various fibrotic disorders, and different forms of cancer. Established by Thomas B. Neff on September 29, 1993, the firm's main offices are situated in San Francisco, California.
KYNB Company Deck
KYNB Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed meaningful clinical progress across two key programs (FG-3246/FG-3180 and roxadustat), supportive subgroup efficacy data, validated mitigation of a key ADC safety issue, improved financial discipline with reduced R&D and SG&A, revenue growth, and a cash runway into 2028. Key risks include ongoing net losses, small revenue base, an unresolved biomarker statistical significance that 'just missed' in the IST, residual safety concerns around neutropenia, and reliance on upcoming binary clinical readouts and enrollment execution. On balance, the positives (clinical signals, validated mitigation strategy, constructive FDA feedback on roxadustat, cash runway and expense reductions) outweigh the lowlights, though the company remains dependent on near-term trial execution.View all KYNB earnings summariesKYNB Stock 12 Month Forecast
Average Price Target
$36.50
▲(398.63% Upside)
Technical Analysis
Ownership Overview
3.37% Insiders
22.61% Mutual Funds
10.71% Other Institutional Investors
59.44% Public Companies and
Individual Investors